Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

By LabMedica International staff writers
Posted on 21 Oct 2026

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. More...

Early-stage tumors are often treated surgically, but recurrence can still occur after surgery or initial therapy. Imaging remains the standard for follow-up, although microscopic disease may not yet be visible on scans. New findings now show that liquid biopsy can detect residual lung cancer signals in blood before radiologic recurrence becomes apparent.

Researchers at NYU Langone Health, NYU Grossman School of Medicine, and the Laura and Isaac Perlmutter Cancer Center evaluated a whole-genome sequencing liquid biopsy approach for monitoring lung cancer recurrence. The test analyzes circulating tumor DNA shed by tumor cells into the bloodstream and tracks tumor-specific whole-genome mutational signatures across serial blood draws. This allows researchers to assess minimal residual disease at different stages of treatment.

The study focused on predicting recurrence of stage IA lung adenocarcinoma using circulating tumor cell–free DNA whole-genome mutational signatures. It found that a positive tumor DNA result served as a highly sensitive biomarker of minimal residual disease, detecting microscopic recurrence months before scans showed physical tumors. A negative result strongly correlated with sustained remission. The article appears online ahead of volume 28, issue 11, November 2026, of The Journal of Molecular Diagnostics, published by Elsevier.

The findings described potential implications across the patient pathway. The blood test results could help identify patients at higher or lower risk earlier, guide targeted treatment for detectable residual disease, and potentially spare patients with clear results from unnecessary overtreatment and toxicity. The study also described the value of earlier relapse detection when disease burden is extremely low.

“As a surgeon, I follow my patients very closely, and I want to know as soon as possible if the cancer has come back. Unfortunately, even the earliest stage patients risk recurrence. Our study’s findings highlight just how sensitive and specific liquid biopsy can be when integrated into routine post-treatment monitoring, even in the earliest stages of lung cancer. This is of critical importance for deciding on post-operative treatments,” said Harvey I. Pass, MD, Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY.

Related Links
Grossman School of Medicine
Perlmutter Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.